- Disc Medicine to Participate in the Jefferies Global Healthcare Conference
- Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress
- Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference
- Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
- Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
- Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
- Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer
- Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
- Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera
More ▼
Key statistics
On Friday, Disc Medicine Inc (IRON:NMQ) closed at 39.12, 52.81% above the 52 week low of 25.60 set on Apr 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 36.16 |
---|---|
High | 40.20 |
Low | 35.68 |
Bid | 38.00 |
Offer | 50.00 |
Previous close | 36.46 |
Average volume | 389.20k |
---|---|
Shares outstanding | 24.72m |
Free float | 20.24m |
P/E (TTM) | -- |
Market cap | 904.06m USD |
EPS (TTM) | -3.37 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.
More ▼